Functional alteration of the lymphoma stromal cell niche by the cytokine context: Role of indoleamine-2,3 dioxygenase

Cancer Research

Volumn 69, Issue 7, 2009, Pages 3228-3237

  Hajjami, Hélène Maby El ^a   Amé Thomas, Patricia ^a,b   Pangault, Céline ^a,b   Tribut, Olivier ^b   DeVos, John ^c   Jean, Rachel ^b   Bescher, Nadège ^b   Monvoisin, Céline ^a   Dulong, Joëlle ^a,d   Lamy, Thierry ^a,b   Fest, Thierry ^a,b   Tarte, Karin ^a,b  

^a INSERM U917   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; LYMPHOTOXIN ALPHA BETA; TUMOR NECROSIS FACTOR; ALPHA INTERFERON;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; FOLLICULAR LYMPHOMA; GROWTH DISORDER; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE; LYMPHOMA; MESENCHYMAL STEM CELL; MICROENVIRONMENT; PHENOTYPE; PRIORITY JOURNAL; STROMA CELL; B CELL LYMPHOMA; CHILD; ENZYMOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MESODERM; PATHOLOGY;

B-LYMPHOCYTES; CELL SURVIVAL; CHILD; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-ALPHA; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MESODERM; STROMAL CELLS;

EID: 66149099328     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3000     Document Type: Article

References (50)

1. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147
2. Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005;7:393-395
3. Ramasamy R, Lam EW Soeiro I, Tisato V, Bonnet D, Dazzi F Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 2007;21:304-310
4. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003;102:3837-3844
5. Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008;15:730-738
6. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007:449:557-563
7. Mishra PJ, Humeniuk R, Medina DJ, et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem, cells. Cancer Res 2008;68:4331-4339
8. Uccelli A, Moretta L, Pistola V Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006;36:2566-2573
9. Nauta AJ, Fibbe WE Immunomodulatory properties of mesenchymal stromal cells. Blood 2007;110:3499-3506
10. Krampera M Cosmi L Angeli R, et al. Role for IFN-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem. Cells 2006;24: 386-398
11. Ryan JM, Barry F, Murphy JM, Mahon BP Interferon- γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007;149:353-363
12. Polchert D, Sobinsky J, Douglas G, et al. IFN-γ activation of mesenchymal stem ceUs for treatment and prevention of graft versus host disease. Eur J Immunol 2008;38:1745-1755
13. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D Human bone marrow stromal cells Inhibit aUogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619-4621
14. Munn DH, Mellor AL Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117: 1147-1154
15. Selmani Z, Naji A, Zldi I, et al. HLA-G5 secretion by Human mesenchymal, stem cells is required to suppress T-LYMPHOCYTE and NK function and to induce CD4+CD25hlghFOXP3+ regulatory T cells. Stem. Cells 2008;26:212-222
16. Corcione A, Benvenuto F Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107:367-372
17. Rasmusson I, Le Blanc K, Sundberg B, Ringden O Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol 2007;65:336-343
18. Traggiai E, Volpi S, Schena F et al. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated form healthy donors and systemic lupus erythematosus patients. Stem Cells 2008;26:562-569
19. Bajenoff M, Egen JG, Koo LY, et al. Stromal, cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes, immunity 2006;25: 989-1001.
20. Ame-Thomas P, Maby-E Hajjami H, Monvoisin C, et al. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood 2007;109:693-702.
21. Lwin T, Hazlehurst LA, Li Z, et al. Bone marrow stromal, cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-κB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia 2007;21:1521-1531
22. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal, stem, cells ameliorate experimental, autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106:1755-1761
23. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81: 1390-1397
24. Shaffer AL, Rosenwald A, Staudt LM Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002;2:920-932
25. Canioni D, Brice P, Lepage E, et al. Bone marrow histological patterns can predict survival of patients with grade 1. or 2 follicular lymphoma: a study from the Groupe d'Etude des Lymphomes Folliculaires. Br J Haematol 2004;126:364-371
26. Peuchmaur M, Emilie D, Crevon MC, et al. Interleukin-2 and interferon-γ production in follicular lymphomas. Am J Clin Pathol 1991;95:55-62.
27. Warzocha K, Ribeiro P, Renard N, et al. Expression of genes coding for the tumor necrosis factor and lymphotoxin ligand-receptor system in non-Hodgkin's lymphomas. Cancer Immunol Immunother 2000:49: 469-475
28. Widner B, Werner ER, Schennach H Wachter H Fuchs D Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 1997:43: 2424-2426
29. Rohatiner AZ, Gregory WM, Peterson B, et al. Metaanalysis to evaluate the role of interferon in. follicular lymphoma. J Clin Oncol 2005;23:2215-2223
30. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC Novel tryptophan, catabolic enzyme ID02 is the preferred biochemical target of the antitumor indoleamine 2,3-dloxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007:67:7082-7087
31. Terness P, Bauer TM, Rose L et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3- dioxygenase-expresslng dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002;196:447-457
32. Schmitter D, Koss M, Niederer E, Stahel RA, Plchert G T-cell derived cytokines co-stimulate proliferation of CD40-activated germinal centre as well as follicular lymphoma cells. Hematol Oncol 1997;15:197-207.
33. Andersen NS, Larsen JK, Christiansen J, et al. Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. Blood 2000;96:2219-2225
34. Dierks C, Grbic J, Zirlik K, et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007;13:944-951
35. Adikarl SB, Lian H, Link H, Huang YM, Xiao BG Interferon-γ-m. odlfled dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis. Clin Exp Immunol 2004;138:230-236
36. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan, degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-1274
37. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC Inhibition of Indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Binl, potentiates cancer chemotherapy. Nat Med 2005;11:312-319
38. Riesenberg R, Weiler C, Spring O, et al. Expression, of indoleamine 2,3-dioxygenase in tumor endothelial, cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res 2007;13: 6993-7002.
39. Haniffa MA, Wang XN, Holtick U, et al. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol 2007;179:1595-1604
40. Jones S, Horwood N., Cope A, Dazzi F The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol 2007;179:2824-2831
41. Lob S, Konigsralner A, Schafer R, Rammensee HG, Opelz G, Temess P. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells.
42. Scheler M, Wenzel J, Tuting T, Takikawa O, Bieber T, von Bubnoff D. Indoleamine 2,3-dioxygen.ase (IDO): the antagonist of type I interferon-driven skin inflammation? Am. J Pathol 2007;171:1936-1943.
43. Dummer R, Hassel JC, Fellenberg F, et al. Adenovirusmediated intralesional interferon-γ gene transfer induces tumor regressions In cutaneous lymphomas. Blood 2004;104:1631-1638
44. Ohata J, Zvaifler NJ, Nlshio M1 et al. Fibroblast-like synoviocytes of mesenchymal origin, express functional. B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005:174:864-870.
45. Djouad F1 Fritz V Apparailly F1 et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor a in collagen-induced arthritis. Arthritis Rheum. 2005;52:1595-1603.
46. Babcock TA, Carlin JM. Transcriptional activation of indoleamine dioxygenase by interleukln 1 and tumor necrosis factor a in interferon-treated epithelial cells. Cytokine 2000:12:588-594.
47. Byers RJ, Sakhinla E, Joseph P, et al. Clinical quantitation of immune signature in follicular lympho- ma by RT-PCR based gene expression profiling Blood 2008;111:4764-4770.
48. Alvaro T, Lejeune M, Salvado MT, et al. Immunohis- tochemical. patterns of reactive mlcroenvlronment are associated with clinicobiologic behavior in foUicular lymphoma patients. J Clin Oncol 2006;24:5350-5357.
49. Dave SS, Wright G, Tan B, et al. Prediction, of survival in foUicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl. J Med 2004:351: 21.59-69.
50. Wahlin BE, Sander B, Christensson. B, KimbyE. C.D8+ T-cell content in. diagnostic lymph nodes measured by flow cytometry is a predictor of survival in foUicular lymphoma. Clin Cancer Res 2007;13:388-397.